FDA Approves Cimzia (certolizumab pegol) for the Treatment for Non-Radiographic Axial Spondyloarthritis

Brussels, Belgium– 29 March 2019– UCB, a global biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved extending the label for Cimzia (certolizumab pegol) to include a new indication...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news